This Healthcare Stock Fell 24% After Earnings. One Fund Bought $51 Million Before the Drop

Van Berkom & Associates initiated a new 1,587,636-share position in Option Care Health, valued at an estimated $51.54 million based on quarterly average prices, equal to 1.41% of the fund’s AUM. The stock has since fallen about 24% after the company’s Q1 earnings release, which showed revenue up just 1.3% year over year to $1.35 billion, adjusted EBITDA down 6.3% to $104.8 million, and full-year revenue guidance cut to $5.675 billion-$5.775 billion. The filing is a long-term bullish bet on a beaten-down healthcare name, but recent operating results and guidance are clearly negative.

Analysis

This looks less like a clean vote of confidence and more like a price-dislocation trade by a quality-oriented allocator. The important second-order read is that a large, disciplined buyer entered before the earnings reset, which means the stock is now being re-underwritten by the market at a materially lower base while the fundamental debate has shifted from valuation to growth durability. In that setup, incremental supply from disappointed holders can keep pressure on the name for several weeks, but it also creates a sharper rebound path if management can simply stabilize growth expectations over the next 1-2 quarters.

The core risk is that home infusion is a quasi-defensive business, but the market is pricing it like a cyclical growth slowdown because operating leverage works both ways. If revenue remains near low-single-digit growth while margins compress, the re-rating can continue despite the company’s scale advantage. The credit facility expansion and buybacks help liquidity and signal balance-sheet confidence, but they do not solve the central issue: investors need evidence that reimbursement mix, patient volumes, or therapy intensity can reaccelerate before multiple compression becomes a value trap.

The contrarian angle is that consensus may be over-penalizing a temporary digestion period in a structurally attractive category. The company’s national footprint and service complexity are hard to replicate, so a normalized growth profile could justify a meaningfully higher multiple than the current tape implies. That said, the fastest money is likely made not by buying outright today, but by waiting for either a post-earnings base or a clearer guide-up/down inflection in the next print.

Key Decisions for Investors

• Avoid chasing OPCH immediately; wait 2-6 weeks for post-earnings selling to exhaust, then consider a starter long only if the stock holds recent lows and volume fades. Risk/reward improves materially if downside momentum stalls near the first support zone.
• For tactical upside, buy OPCH 3-6 month call spreads rather than stock to express a rebound thesis with defined risk. This fits a scenario where sentiment repairs faster than fundamentals.
• If you want the cleaner relative-value expression, pair long OPCH vs. short a slower-growing healthcare services name with more stretched expectations, using OPCH as the catch-up leg only after stabilization. The thesis is mean reversion in a discounted quality compounder, not broad sector beta.
• Do not add aggressively until the next quarterly data point confirms either volume stabilization or margin containment; otherwise the stock remains vulnerable to another 10-15% de-rating on any guidance disappointment.
• Monitor insider/fund positioning over the next filing cycle; if additional high-quality holders average down while the stock base-builds, that is the highest-conviction entry signal.